Picture of blood cells

Open Access research which pushes advances in bionanotechnology

Strathprints makes available scholarly Open Access content by researchers in the Strathclyde Institute of Pharmacy & Biomedical Sciences (SIPBS) , based within the Faculty of Science.

SIPBS is a major research centre in Scotland focusing on 'new medicines', 'better medicines' and 'better use of medicines'. This includes the exploration of nanoparticles and nanomedicines within the wider research agenda of bionanotechnology, in which the tools of nanotechnology are applied to solve biological problems. At SIPBS multidisciplinary approaches are also pursued to improve bioscience understanding of novel therapeutic targets with the aim of developing therapeutic interventions and the investigation, development and manufacture of drug substances and products.

Explore the Open Access research of SIPBS. Or explore all of Strathclyde's Open Access research...

The role of IL-4R alpha signalling during toxoplasma gondii infection

Mokgethi, T. and Nickdel, M.B. and Henriquez, F.L. and Roberts, F. and Brombacher, F. and Roberts, Craig and Alexander, J. (2008) The role of IL-4R alpha signalling during toxoplasma gondii infection. Immunology, 125 (s1). p. 110. ISSN 0019-2805

Full text not available in this repository.Request a copy from the Strathclyde author

Abstract

The protective immune response against Toxoplasma gondii is widely recognised as being type-1 mediated. Nevertheless, the overproduction of type-1 cytokines can induce severe pathology. The extent to which Th2 cytokines can modulate the disease protective versus disease exacerbating effects of type-1 cytokines remains to be resolved. We have therefore, compared the disease induced by T. gondii cysts in IL-4)/), IL-4Ra)/), and wild-type BALB/c mice, a mouse strain normally resistant to this disease. Increased mortality and increased lung pathology were observed in the absence of IL-4 and signalling via IL-4Ra and splenocyte type 1 cytokine and NO production was increased during early infection (day 12). IL-4 can modulate type-1 inflammatory responses by counter-regulating the effects of IFN-c on CD4+ T cells and/or macrophages.